| Name | Title | Contact Details |
|---|
CatalystRx is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Philadelphia, PA. To find more information about CatalystRx, please visit www.catalystrx.com
VascuCare is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Formativ Health is a management services organization that is redefining Practice Management and end-to-end Revenue Cycle through the integration of technology-enabled Patient Access, Revenue Cycle Management, Practice Operations and Advisory Services. At Formativ Health our approach is simple: We seek to understand your strategy and business goals so that we can define solutions tailored to your needs and designed to maximize performance. As the health care industry continues to transform, we partner with providers to successfully improve their financial health, adapt to changing risk-based payment models, increase physician productivity and satisfaction, and enhance the patient experience. Our technology-enabled services are designed to provide flexibility across the full continuum of Practice Management and Revenue Cycle
delta flex travelers is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.